• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Magenta Therapeutics, Inc. - Common Stock (NQ:MGTA)

    N/A UNCHANGED
    Last Price Updated: 4:00 PM EDT, Sep 11, 2023 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Magenta Therapeutics, Inc. - Common Stock

    MAGENTA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Magenta Therapeutics, Inc. - MGTA
    From Kahn Swick & Foti, LLC
    Via Business Wire
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Cvent Holding Corp. (Nasdaq - CVT), Absolute Software Corporation (Nasdaq – ABST), Home Point Capital, Inc. (Nasdaq – HMPT), Magenta Therapeutics, Inc. (Nasdaq –
    From Brodsky & Smith LLC
    Via GlobeNewswire
    MAGENTA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Magenta Therapeutics, Inc. - MGTA
    From Kahn Swick & Foti, LLC
    Via Business Wire
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ruth’s Inc. (Nasdaq – RUTH), Magenta Therapeutics, Inc. (Nasdaq – MGTA), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    MGTA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Magenta Therapeutics, Inc. Is Fair to Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    Magenta Therapeutics Reports First Quarter Financial Results, Early Clinical Observations from MGTA-117 Clinical Trial and Other Program Highlights
    From Magenta Therapeutics
    Via Business Wire
    InvestorNewsBreaks – Magenta Therapeutics Inc. (NASDAQ: MGTA) Featured in Mizuho Securities Research Report
    Via Investor Brand Network
    Magenta Therapeutics Focuses R&D and Operational Spending, Reduces Workforce and Extends Cash Runway
    From Magenta Therapeutics
    Via Business Wire
    Magenta Therapeutics Highlights Recent Pipeline Progress and Milestone Expectations for 2022
    From Magenta Therapeutics
    Via Business Wire
    Magenta Therapeutics to Present at the J.P. Morgan Healthcare Conference and the B. Riley Virtual Oncology Conference
    From Magenta Therapeutics
    Via Business Wire
    Magenta Therapeutics Highlights Presentations of Data Related to Stem Cell Mobilization and Targeted Conditioning at the 2021 American Society of Hematology (ASH) Annual Meeting
    From Magenta Therapeutics
    Via Business Wire
    Magenta Therapeutics Reports Third Quarter Financial Results and Program Highlights
    From Magenta Therapeutics, Inc.
    Via Business Wire
    Magenta Therapeutics Announces Data Presentations Related to its Mobilization and Conditioning Programs at the 2021 American Society of Hematology (ASH) Annual Meeting
    From Magenta Therapeutics
    Via Business Wire
    Magenta Therapeutics Appoints Jeffrey Humphrey, M.D. as Chief Medical Officer
    From Magenta Therapeutics, Inc.
    Via Business Wire
    Magenta Therapeutics to Participate in 2021 Cantor Virtual Global Healthcare Conference
    From Magenta Therapeutics, Inc.
    Via Business Wire
    Magenta Therapeutics Announces IND Clearance for MGTA-117 Targeted Conditioning Clinical Trial
    From Magenta Therapeutics, Inc.
    Via Business Wire
    Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights
    From Magenta Therapeutics, Inc.
    Via Business Wire
    Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in August
    From Magenta Therapeutics, Inc.
    Via Business Wire
    Magenta Therapeutics Announces Update on U.S. FDA Investigational New Drug Application for MGTA-117 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome
    From Magenta Therapeutics, Inc.
    Via Business Wire
    Magenta Therapeutics Appoints Caren Deardorf as Chief Commercial Officer
    From Magenta Therapeutics, Inc.
    Via Business Wire
    Magenta Therapeutics Appoints Thomas Beetham as Chief Legal Officer
    From Magenta Therapeutics
    Via Business Wire
    Magenta Therapeutics Announces Additional Preliminary Positive Results from Ongoing Phase 2 Clinical Trial of MGTA-145 and Plerixafor in Patients with Multiple Myeloma at the American Society of Clinical Oncology (ASCO) Annual Meeting
    From Magenta Therapeutics
    Via Business Wire
    Magenta Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
    From Magenta Therapeutics
    Via Business Wire
    Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in May
    From Magenta Therapeutics
    Via Business Wire
    Magenta Therapeutics Announces Positive Preliminary Results from Phase 2 Clinical Trial of MGTA-145 in Multiple Myeloma and Provides an Update on its Anticipated Clinical Study with MGTA-117
    From Magenta Therapeutics
    Via Business Wire
    Magenta Therapeutics Announces $86.4 Million Common Stock Investment from Multiple Investors
    From Magenta Therapeutics, Inc.
    Via Business Wire
    Magenta Therapeutics Reports First Quarter Financial Results and Recent Program Highlights
    From Magenta Therapeutics
    Via Business Wire
    Magenta Therapeutics Appoints David Nichols as Chief Technical Officer
    From Magenta Therapeutics
    Via Business Wire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.